Intellia Therapeutics, Inc.
NTLAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIntellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company carries a $1.79B market cap, placing it firmly in the small-cap category. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing.
Market Cap
$1.79B
Beta
1.82
P/E (TTM)
—
P/E (Fwd)
-4.90
EPS (TTM)
$-3.34
EPS (Fwd)
$-2.60
ROE
-55.4%
ROA
-30.1%
Cash
$437.8M
Total Debt
$73.4M
Free CF
-$249.8M
52W Change
12.8%
Annual Financials
Cash vs Debt
Where NTLA stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, NTLA finished 1.05% above its 150-day moving average ($13.37) and 8.78% above its 200-day moving average ($12.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTLA overbought or oversold?
At the August 26, 2026 close, NTLA's RSI(14) was 70.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intellia Therapeutics, Inc. holds $437.8M in cash against $73.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$249.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -55.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $33.1M (2021) to $67.7M (2025), reflecting a 105% increase over the period.
With a beta above 1.5, NTLA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NTLA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Intellia Therapeutics, Inc.'s trajectory.